DTaP Pediatric Infanrix, Kinrix, Havrix, Hiberix, Bexsero, Boostrix, Menveo-one®. CDC Federal Contract Number: 75D30125D00198, Manufacturer…

Texas has awarded contract HHSTX-6-0000397116 to GlaxoSmithKline Financial, effective March 11, 2026, for the supply of pediatric immunization vaccines under the state's Vaccine Services Group program. The contract encompasses multiple vaccine formulations including DTaP (Diphtheria, Tetanus, and Pertussis) combination products marketed as Infanrix, Kinrix, Havrix, Hiberix, Bexsero, Boostrix, and Menveo-one. This award aligns with the underlying federal General Services Administration contract numbered 75D30125D00198 and operates under the authority of Texas Government Code Section 2155.144. The vaccines supplied under this contract fall within the Serums, Toxoids, and Vaccines category (National Institute of Governmental Purchasing Code 26980).

GlaxoSmithKline Financial will serve as the prime contractor delivering these immunological products to support Texas's pediatric immunization programs. The specific contract values, annual amounts, and detailed performance periods were not disclosed in the available documentation. The supplier classification and procurement coding indicate this contract addresses critical public health requirements for routine childhood vaccinations throughout the State of Texas.